TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02664727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The effects of acute exercise in heavy drinkers
Description: A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The effects of acute exercise in alcoholic patients
Description: A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
Study: NCT01783847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO)
Description: 4000 units per vial

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Just observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl prednisolone
Description: 250 mg every 6 hours for 3 days.
Study: NCT04633798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPL/Lipiflow
Description: To treat patients with MGD using intense pulsed light combined with lipiflow

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPL/MGX
Description: To treat patients with MGD using intense pulsed light combined with meibomian gland massage
Study: NCT03730636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCT dosage
Description: Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
Study: NCT00612469

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Fluoride
Description: Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin hydrochloride
Description: Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin hydrochloride
Description: Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine digluconate
Description: Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
Study: NCT03584568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perspective Taking Reappraisal
Description: Interventions involving 1) appreciating relational insights; 2) enhancing self-awareness; 3) empathetic understanding of care-recipient; 4) integrating self-care and caring for others and 5) negotiation.

Intervention type: OTHER
Group type: OTHER
Intervention: Basic Skill Building
Description: These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Skill Building
Description: These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.
Study: NCT02049164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR08

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR08

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR08

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03788083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimix
Description: Intratumoral TriMix injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intratumoral placebo injection
Study: NCT03527368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding
Description: Participants consume food earlier in the day

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual feeding pattern
Description: Participants consume food later in the day
Study: NCT00676377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: 2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline Placebo
Study: NCT04461483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-935 placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-935 placebo-matching tablets
Study: NCT04623970

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Treatment
Description: Comprehensive dental care (restorative treatmen, crowns, pulp therapy, fissure sealant and teeth extraction for pediatric patients under the deep sedation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Treatment
Description: Comprehensive dental care (restorative treatmen, crowns, pulp therapy, fissure sealant and teeth extraction for pediatric patients under the deep sedation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Treatment
Description: Comprehensive dental care (restorative treatmen, crowns, pulp therapy, fissure sealant and teeth extraction for pediatric patients under the deep sedation
Study: NCT01932567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography
Study: NCT02217332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexpramipexole
Description: Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
Study: NCT02780154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ (7G8) Challenge
Description: PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ (7G8) Challenge
Description: PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ (7G8) Challenge
Description: PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ (7G8) Challenge
Description: PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ (NF54) Challenge
Description: PfSPZ (NF54) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
Study: NCT05539274

Intervention type: DIAGNOSTIC_TEST
Intervention: human papilloma virus testing and genotyping in cervical cancer cases
Description: an observational analytical prospective cross-sectional study was managed from July 2019 to July 2022 on 70 cervical cancer patients collected from gyne-oncology unit in Shatby obstetrics and gynecology university hospital of Alexandria medical school after taking a written consent and following approval by Alexandria medical school institutional ethics committee. All patients were subjected to full history taking as age, gravidity, parity, contraceptive history, medical disease, detailed marital history and smoking. Collection of the sample from all cases of the study for human papilloma virus testing and genotyping was done after diagnostic workup and before treatment of the study cases at any time in post-menopausal women and at mid cycles period in premenopausal women by cervical smear using PAP spatula and endocervical brush.
Study: NCT04058366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study: NCT01589237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Study: NCT01672723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Study: NCT02314910

Intervention type: OTHER
Intervention: Sample histology
Study: NCT03081052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iNO
Description: Subject will receive inhaled Nitric Oxide in this intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iNO
Description: Subject will receive inhaled Nitric Oxide in this intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iEPO
Description: Subject will receive inhaled Epoprostrenol in this intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iEPO
Description: Subject will receive inhaled Epoprostrenol in this intervention
Study: NCT04150601

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIMEOX
Description: SIMEOX is a device generating a succession of gentle depression at the mouth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEP
Description: A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous Exhalation
Description: A slow vital capacity maneuver will be performed according to the guidelines, from total lung capacity to residual volume
Study: NCT00558194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training
Description: 12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Treatment
Description: 12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
Study: NCT00006373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6
Study: NCT01374438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0160
Description: MSDC-0160 150 mg capsules given once daily for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules given once daily for 90 days
Study: NCT02734875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention arm offers primary care providers additional information on patient risks and benefits as well as an offer of assistance with managing a patient's anticoagulation from a respected service at BWH.
Study: NCT03227913

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two samples of saliva
Description: 1. Without stimulation: the first will be used to measure the flow of naturally secreted saliva~2. With stimulation: the second will will be used to measure the flow and viscosity of the saliva secreted after stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two samples of saliva
Description: 1. Without stimulation: the first will be used to measure the flow of naturally secreted saliva~2. With stimulation: the second will will be used to measure the flow and viscosity of the saliva secreted after stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing behaviour
Description: Measure the time taken by subjects to chew the food and the number of bites they use before swallowing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing behaviour
Description: Measure the time taken by subjects to chew the food and the number of bites they use before swallowing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study of the food bolus
Description: * Analysis by a compression and viscosity test~* Evaluation of the quantity of saliva incorporated by drying

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study of the food bolus
Description: * Analysis by a compression and viscosity test~* Evaluation of the quantity of saliva incorporated by drying
Study: NCT00006373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Study: NCT03667378

Intervention type: BEHAVIORAL
Intervention: Quality of Communication (QOC)
Description: Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).

Intervention type: BEHAVIORAL
Intervention: Quality of Communication (QOC)
Description: Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
Study: NCT00006373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6
Study: NCT03667378

Intervention type: BEHAVIORAL
Intervention: visits with a supportive care clinician
Description: Monthly visits with a supportive care clinician
Study: NCT02708836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction of anesthesia
Description: At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induction of anesthesia
Description: At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]
Description: By standard method. Sizing at the discretion of the primary anesthesiologist.
Study: NCT04734093

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of sonographic signs of gouty arthritis
Description: the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.
Study: NCT02708836

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy and placement of ETT
Description: Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation via the ETT
Description: Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation via the ETT
Description: Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of the ETT
Description: Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal of the ETT
Description: Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation of the trachea through the LMA
Description: With ETT using fiberoptic bronchoscope guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation via the LMA
Description: After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergence from anesthesia
Description: At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergence from anesthesia
Description: At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand).
Study: NCT02855125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-114
Description: TAS-114 was a modulator of 5-fluorouracil (5-FU).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.
Study: NCT04734093

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of sonographic signs of gouty arthritis
Description: the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of sonographic signs of gouty arthritis
Description: the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of sonographic signs of gouty arthritis
Description: the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of sonographic signs of gouty arthritis
Description: the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of sonographic signs of gouty arthritis
Description: the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of sonographic signs of gouty arthritis
Description: the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of sonographic signs of gouty arthritis
Description: the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.